– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% – – BioLineRx retains rights to develop and commercialize motixafortide in solid...
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
Seaking AlphaSeeking Alpha / Seaking Alpha 6 hours ago 1 Views
Comments